Showing results (141-150 of 566) with videos related to
Sort By:
Pageof 57
The British Journal of Ophthalmology|September 1, 1992
Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal tractionR Walshe, P Esser, P Wiedemann, et al.Medizinische Klinik (Munich, Germany : 1983)|March 15, 1993
[Can nuclear magnetic resonance tomography supplement and expand splenic diagnosis in malignant systemic diseases? Comparison of nuclear magnetic resonance tomography, ultrasound and computerized tomography findings]R Lorenz, J P Hedde, V DiehlBlood|January 15, 1997
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphomaA Engert, V Diehl, R Schnell, et al.International Journal of Clinical Pharmacology and Therapeutics|February 1, 1997
Idarubicin: a brief overview on pharmacology and clinical useP Borchmann, K Hübel, R Schnell, et al.The Cochrane Database of Systematic Reviews|July 22, 2004
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaJ Bohlius, M Reiser, G Schwarzer, et al.The Cochrane Database of Systematic Reviews|January 10, 2003
Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphomaJ Bohlius, M Reiser, G Schwarzer, et al.Cancer Genetics and Cytogenetics|June 1, 1987
Translocation (6;9)(p23;q34) in smoldering leukemia and acute nonlymphocytic leukemiaC Fonatsch, B Stollmann, J Holldack, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2002
Current strategies of antibody-based treatment in Hodgkin's diseaseR Schnell, P Borchmann, H Schulz, et al.Medizinische Klinik (Munich, Germany : 1983)|April 18, 1998
[Pathogenesis and therapy of Hodgkin lymphoma]H Tesch, H Bohlen, J Wolf, et al.Onkologie|September 16, 2003
Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literatureH Pels, H Schulz, U Schlegel, et al.Pageof 57